Happy New Year ANP punters!
Unfortunately the bot has not gone anywhere.
What a contrasting trading pattern compared to peers such as IHL, IMU, ACW etc.
Just quickly on the Cancer reference - ANP has mentioned a few times that they see great potential for ATL1102 in other "Fibrotic" diseases.
Well, Fibrosis is a key pillar in many Cancers.
In many of the early pith decks, Cancer was an indication mentioned by Diamond.
Let's see how the Board navigates the waters this year...
While Dr G. is correct in saying "we want to own the DMD space"...it would also be wise to spread the risk into multiple programs.
The AGM messaging was non committal on anything outside of EMEA P3 for DMD - the Board seems to be hedging bets.
The more time goes by without Sarepta spending any of their $2B cash...the more the likelihood Sarepta will become involved in our program at some stage.
Good luck all.
.
- Forums
- ASX - By Stock
- PER
- UPDATE ON PFIZER’S PHASE 1B OPEN-LABEL MINI-DYSTROPHIN GENE THERAPY TRIAL FOR DUCHENNE
UPDATE ON PFIZER’S PHASE 1B OPEN-LABEL MINI-DYSTROPHIN GENE THERAPY TRIAL FOR DUCHENNE, page-14
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.0¢ |
Change
-0.001(1.23%) |
Mkt cap ! $72.12M |
Open | High | Low | Value | Volume |
8.2¢ | 8.2¢ | 8.0¢ | $63.52K | 777.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 43377 | 8.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.2¢ | 97561 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 43377 | 0.080 |
2 | 212658 | 0.078 |
1 | 200000 | 0.077 |
3 | 91500 | 0.076 |
4 | 206988 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.082 | 97561 | 1 |
0.083 | 214000 | 1 |
0.084 | 67142 | 2 |
0.085 | 141000 | 2 |
0.086 | 106100 | 2 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
PER (ASX) Chart |